MSD/Mepha deal sees Swiss launch of generic losartan
This article was originally published in Scrip
Executive Summary
The Swiss company Mepha has launched a generic version of Merck & Co's antihypertensive, Cozaar (losartan potassium), in Switzerland under an agreement with the US firm's European subsidiary, Merck Sharp & Dohme. The move is expected to help mitigate the effects on Merck of the product's patent expiry later this year, while giving Mepha early access to the valuable losartan market.